fashion -WSS

fashion

author：comprehensive 2025-10-02 17:22:51 - browse：934

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Cell therapy fails to slow type 1 diabetes, but safety is established

focus

WSS

FTC falls short on scrutinizing hospital mergers, study says

Bird flu outbreak in cows is latest avian flu curveball

H5N1 bird flu virus started spreading in cows in Texas in December

Why rehabilitation engineers need to center patients in their research

CRISPR base editing slashes cholesterol levels in monkeys

Exact Sciences stock tumbles despite strong cancer detection sales

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Study points to new risk in gene therapy death of Terry Horgan

Walensky prepares to leave CDC — and Congress — behind

Lawsuit highlights wrinkle for disputes over surprise medical bills

Medical records are filled with copy

6 solutions to address cancer drug shortages and others

Hepatitis C has a cure — but many Americans still lack access to it

Why rehabilitation engineers need to center patients in their research

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Medical bills so high, Medicare adding extra digits to claim forms

leisure time

Setback for rare diseases as Taysha Gene Therapies pulls back

Lawsuit highlights wrinkle for disputes over surprise medical bills

MassMutual is introducing free genetic testing for members

Why does health care cost so much? A reading guide

Q&A: Jennifer Adair on making gene therapy available globally

What will Novo Nordisk's VC do with its influx of cash?

explore

focus

focus

hotspot